Search for: "K-V Pharmaceutical Company"
Results 121 - 140
of 221
Sort by Relevance
|
Sort by Date
12 Sep 2012, 4:58 am
Ask A Man Who Can – http://bit.ly/NfTBwl (Charles Holloway) Avoid the Pitfalls of Self-Managing eDiscovery – http://bit.ly/Qrd0tX (Andrew Hinkes) Backgrounder Update: Technology Assisted Review Compendium – Feb. 1 – Sept. 10, 2012 – http://bit.ly/IiTGtb (@OrangeLT) Criminal E-Discovery: 21st Century Paperless Trails (Part 3 of 5) http://bit.ly/NmjN8L (Daniel Garrie) Drilling Down Into Texas Electronic Discovery http://bit.ly/PLxRG3 (Timothy Mountz, Charles Strecker)… [read post]
11 Sep 2012, 12:25 pm
In K-V Pharmaceutical Co. v. [read post]
6 Sep 2012, 5:25 pm
District Court for the District of Columbia dealt a blow to K-V Pharmaceutical Company’s (“KV’s”) efforts to “restore” orphan drug exclusivity for the pre-term birth drug MAKENA (hydroxyprogesterone caproate) Injection, 250 mg/mL, by granting FDA’s Motion to Dismiss a case filed by KV back in early July. [read post]
29 Aug 2012, 10:09 pm
District Court for the District of New Jersey concerning Wyeth Pharmaceuticals Inc. [read post]
24 Aug 2012, 7:46 pm
In the high-profile “K-Dur” case of Merck & Co., Inc., v. [read post]
13 Aug 2012, 1:13 am
On August 1, 2012, Southern District of Florida Judge Marcia Cook, in the securities class action lawsuit involving Jiangbo Pharmaceuticals, granted the motions to dismiss of the company’s CFO, Elsa Sung, and of its auditor. [read post]
13 Aug 2012, 1:13 am
On August 1, 2012, Southern District of Florida Judge Marcia Cook, in the securities class action lawsuit involving Jiangbo Pharmaceuticals, granted the motions to dismiss of the company’s CFO, Elsa Sung, and of its auditor. [read post]
7 Aug 2012, 7:43 pm
Karst – We were eager to delve into the Federal Circuit’s recent 2-1 decision in Momenta Pharmaceuticals, Inc. v. [read post]
7 Aug 2012, 4:10 am
Rufo v. [read post]
23 Jul 2012, 12:00 pm
" FBI Assistant Director in Charge Janice K. [read post]
20 Jul 2012, 12:26 pm
Schering-Plough Corp. v. [read post]
9 Jul 2012, 2:00 am
We also discuss a First Circuit decision affirming the dismissal of a securities fraud action against Textron; a Second Circuit ruling addressing the standard for pleading a failure to disclose “known uncertainties” under Item 303 of Regulation S-K; and an Eighth Circuit decision reversing the dismissal of a securities fraud action against KV Pharmaceutical Company. [read post]
9 Jul 2012, 2:00 am
We also discuss a First Circuit decision affirming the dismissal of a securities fraud action against Textron; a Second Circuit ruling addressing the standard for pleading a failure to disclose “known uncertainties” under Item 303 of Regulation S-K; and an Eighth Circuit decision reversing the dismissal of a securities fraud action against KV Pharmaceutical Company. [read post]
8 Jul 2012, 7:01 pm
Karst – In a rare lawsuit against FDA involving the Orphan Drug Act of 1983, as amended, K-V Pharmaceutical Company (“KV”) and its wholly-owned subsidiary, Ther-Rx Corporation (“Ther-Rx”), filed a Complaint and a Motion for Temporary Restraining Order and Preliminary Injunction in the U.S. [read post]
22 Jun 2012, 3:22 pm
In light of this requirement, pharmaceutical companies have long focused their direct marketing efforts on physicians. [read post]
15 May 2012, 3:12 pm
However, the Commission scrapped such investigations into AstraZeneca and Swiss peer Nycomed in March this year after failing to find evidence that the companies had undertaken such deals. [read post]
7 May 2012, 5:00 am
Mylan Pharmaceuticals, Inc., ___ F. [read post]
1 May 2012, 6:49 pm
That issue, on which the 4th DCA had the first word among Florida appellate courts in its 2011 decision in Kingsway Amigo Insurance Company v. [read post]
29 Apr 2012, 7:31 pm
K-V Pharmaceutical Company, C.A. [read post]
25 Apr 2012, 1:56 pm
The text of the April 25, 2012, decision in FTC v. [read post]
